RGNX
$8.64
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...
Recent News
Biotech Stocks Rally on Departure of Polarizing FDA Official
Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division and blocked several rare-disease drugs from receiving accelerated approval. Prasad’s stance had weighed heavily on the stocks of companies developing the drugs. Now those stocks are rallying after FDA Commissioner Marty Makary said Friday in an interview that Prasad will be departing at the end of April.
uniQure stock surges 36% on FDA official’s departure
Investing.com -- uniQure BV (NASDAQ:QURE) shares surged 36% Monday following reports that the head of the US Food and Drug Administration’s division of vaccines and gene therapies is leaving the agency, prompting multiple analyst upgrades across the biotech sector. REGENXBIO (NASDAQ:RGNX) rose 13% and Biohaven (NYSE:BHVN) gained 23%.
REGENXBIO Q4 Earnings Call Highlights
REGENXBIO (NASDAQ:RGNX) outlined a slate of near-term clinical catalysts and provided financial updates during its fourth-quarter and year-end 2025 earnings call, emphasizing what management described as a “pivotal year” ahead as the company advances late-stage programs in Duchenne muscular dystroph
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience
Regenxbio Inc (RGNX) showcases robust pipeline progress and financial stability, despite regulatory challenges.
REGENXBIO Inc. Q4 2025 Earnings Call Summary
Moby summary of REGENXBIO Inc.'s Q4 2025 earnings call